Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Lance Leon Munn, Ph.D.

Co-Author

This page shows the publications co-authored by Lance Munn and Dan Duda.
Connection Strength

1.146
  1. Placental growth factor promotes tumour desmoplasia and treatment resistance in intrahepatic cholangiocarcinoma. Gut. 2021 Jan 11.
    View in: PubMed
    Score: 0.241
  2. Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma. J Immunother Cancer. 2020 11; 8(2).
    View in: PubMed
    Score: 0.238
  3. Can we identify predictive biomarkers for antiangiogenic therapy of cancer using mathematical modeling? J Natl Cancer Inst. 2013 Jun 05; 105(11):762-5.
    View in: PubMed
    Score: 0.142
  4. A protocol for phenotypic detection and characterization of vascular cells of different origins in a lung neovascularization model in rodents. Nat Protoc. 2008; 3(3):388-97.
    View in: PubMed
    Score: 0.098
  5. Differential transplantability of tumor-associated stromal cells. Cancer Res. 2004 Sep 01; 64(17):5920-4.
    View in: PubMed
    Score: 0.077
  6. Combining microenvironment normalization strategies to improve cancer immunotherapy. Proc Natl Acad Sci U S A. 2020 02 18; 117(7):3728-3737.
    View in: PubMed
    Score: 0.056
  7. Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. Proc Natl Acad Sci U S A. 2016 Apr 19; 113(16):4476-81.
    View in: PubMed
    Score: 0.043
  8. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A. 2012 Oct 23; 109(43):17561-6.
    View in: PubMed
    Score: 0.034
  9. Neovascularization after irradiation: what is the source of newly formed vessels in recurring tumors? J Natl Cancer Inst. 2012 Jun 20; 104(12):899-905.
    View in: PubMed
    Score: 0.033
  10. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev. 2011 Jul; 91(3):1071-121.
    View in: PubMed
    Score: 0.031
  11. Is vasculogenesis crucial for the regrowth of irradiated tumours? Nat Rev Cancer. 2011 Jun 24; 11(7):532.
    View in: PubMed
    Score: 0.031
  12. Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models. Microcirculation. 2010 Apr; 17(3):206-25.
    View in: PubMed
    Score: 0.029
  13. Paradoxical effects of PDGF-BB overexpression in endothelial cells on engineered blood vessels in vivo. Am J Pathol. 2009 Jul; 175(1):294-302.
    View in: PubMed
    Score: 0.027
  14. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol. 2009 May 20; 27(15):2542-52.
    View in: PubMed
    Score: 0.027
  15. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol. 2005 Nov 01; 23(31):8136-9.
    View in: PubMed
    Score: 0.021
  16. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004 Feb; 10(2):145-7.
    View in: PubMed
    Score: 0.019
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.